Mirador Therapeutics
Mark McKenna currently holds various executive positions in the biotechnology and pharmaceutical industries. With a strong background in sales, operations, and business development, Mark has demonstrated leadership in companies such as Mirador Therapeutics, Apogee Therapeutics, and Prometheus Biosciences. Mark also has experience in strategic planning and revenue management in roles at Bausch + Lomb and Salix Pharmaceuticals. Mark's educational background includes an MBA from Azusa Pacific University and participation in the Wharton Fellows Program at The Wharton School.
This person is not in any offices
Mirador Therapeutics
Mirador is a next-generation precision medicine company focused on immunology and inflammation. The company’s Mirador360 TM precision development engine leverages the latest advances in human genetics and cutting-edge data science to rapidly advance new precision medicines for patients living with chronic immune-mediated inflammatory and fibrotic diseases. Launched in 2024, Mirador has raised over $400 million from leading life sciences investors and is based in San Diego, CA.